Remission of Type 2 Diabetes Feasible for Primary Care

This article originally appeared here.
Share this content:
Remission of Type 2 Diabetes Feasible for Primary Care
Remission of Type 2 Diabetes Feasible for Primary Care

TUESDAY, Dec. 5, 2017 (HealthDay News) -- Intensive weight management implemented in primary care practices can result in remission of type 2 diabetes for almost half of patients, according to a study published online Dec. 5 in The Lancet.

Michael E.J. Lean, M.D., from the University of Glasgow in the United Kingdom, and colleagues randomized 49 primary care practices in a 1:1 ratio to provide a weight management program (intervention) or best-practice care by guidelines (control). A total of 306 individuals aged 20 to 65 years who had been diagnosed with type 2 diabetes in the past six years, had a body mass index of 27 to 45 kg/m², and were not receiving insulin were recruited.

The researchers recorded weight loss of 15 kg or more in 24 participants in the intervention group and none in the control group at 12 months (P < 0.0001). Diabetes remission was achieved by 46 and 4 percent of participants in the intervention and control groups, respectively (odds ratio, 19.7). In the whole study population, remission varied with weight loss; remission was achieved by none of those who gained weight, 7, 34, 57, and 86 percent of participants who maintained 0 to 5 kg weight loss, had 5 to 10 kg weight loss, had 10 to 15 kg weight loss, and who lost 15 kg or more, respectively.

"Remission of type 2 diabetes is a practical target for primary care," the authors write.

Several disclosed financial ties to the pharmaceutical and weight loss industries.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab &#43; Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »